Wang L - Search Results

1

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L. Marin D, et al. Among authors: wang l. J Clin Oncol. 2012 Jan 20;30(3):232-8. doi: 10.1200/JCO.2011.38.6565. Epub 2011 Nov 7. J Clin Oncol. 2012. PMID: 22067393 Free PMC article.

2

Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.

Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE. Wang L, et al. Br J Haematol. 2002 Sep;118(3):771-7. doi: 10.1046/j.1365-2141.2002.03705.x. Br J Haematol. 2002. PMID: 12181044 Free article.

3

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.

Wang L, Pearson K, Ferguson JE, Clark RE. Wang L, et al. Br J Haematol. 2003 Mar;120(6):990-9. doi: 10.1046/j.1365-2141.2003.04200.x. Br J Haematol. 2003. PMID: 12648069 Free article.

4

BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation.

Butt NM, Wang L, Abu-Eisha HM, Christmas SE, Clark RE. Butt NM, et al. Among authors: wang l. Blood. 2004 Apr 15;103(8):3245. doi: 10.1182/blood-2003-11-4086. Blood. 2004. PMID: 15070713 Free article. No abstract available.

5

Active transport of imatinib into and out of cells: implications for drug resistance.

Thomas J, Wang L, Clark RE, Pirmohamed M. Thomas J, et al. Among authors: wang l. Blood. 2004 Dec 1;104(12):3739-45. doi: 10.1182/blood-2003-12-4276. Epub 2004 Aug 17. Blood. 2004. PMID: 15315971 Free article.

6

hOCT 1 and resistance to imatinib.

Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. Crossman LC, et al. Among authors: wang l. Blood. 2005 Aug 1;106(3):1133-4; author reply 1134. doi: 10.1182/blood-2005-02-0694. Blood. 2005. PMID: 16033955 Free article. No abstract available.

7

Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.

Butt NM, Rojas JM, Wang L, Christmas SE, Abu-Eisha HM, Clark RE. Butt NM, et al. Among authors: wang l. Haematologica. 2005 Oct;90(10):1315-23. Haematologica. 2005. PMID: 16219567

8

The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.

Wang L, Knight K, Lucas C, Clark RE. Wang L, et al. Haematologica. 2006 Feb;91(2):235-9. Haematologica. 2006. PMID: 16461309

9

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, Wang L, Clark RE. Lucas CM, et al. Among authors: wang l. Haematologica. 2009 Oct;94(10):1362-7. doi: 10.3324/haematol.2009.009134. Epub 2009 Aug 27. Haematologica. 2009. PMID: 19713230 Free PMC article.

10

A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers.

Dunwell T, Hesson L, Rauch TA, Wang L, Clark RE, Dallol A, Gentle D, Catchpoole D, Maher ER, Pfeifer GP, Latif F. Dunwell T, et al. Among authors: wang l. Mol Cancer. 2010 Feb 25;9:44. doi: 10.1186/1476-4598-9-44. Mol Cancer. 2010. PMID: 20184741 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

144,664 results

Search Page

Filters